Tenofovir News and Research

RSS

Research leverages emergency room visits to connect at risk populations to preventive services

With a disproportionate number of black cisgender women in the U.S. becoming HIV positive, researchers at The University of Texas Health Science Center at Houston are sharing critical health information through an atypical venue: the emergency room.

3 Dec 2019

Study finds fewer new cases of HCV in HIV-negative men who have sex with PrEP-using men

Data from a new study presented this week at The Liver Meeting – held by the American Association for the Study of Liver Diseases – found fewer new cases of hepatitis C infection (commonly called HCV), despite very high rates of other sexually-transmitted infections, in HIV-negative men who have sex with men who take pre-exposure prophylaxis (PrEP) treatments.

10 Nov 2019

90% of hepatitis cases, 65% hepatitis deaths preventable by 2030

A new report by the World Health Organization (WHO) shows that 4.5 million deaths could be prevented by 2030, and 26 million beyond that, if 67 countries in the low- and middle-income bracket invest $6 billion a year towards abolishing hepatitis. Hepatitis is a completely preventable and treatable illness at present, and in fact, hepatitis C is completely curable.

29 Jul 2019

Tailored adherence strategies needed to engage young African women in consistent PrEP use

In a study of open-label Truvada as daily pre-exposure prophylaxis (PrEP) to prevent HIV among 427 young African women and adolescent girls, 95% initiated the HIV prevention strategy, and most used PrEP for the first three months.

24 Jul 2019

FDA approves two-drug complete regimen for previously untreated HIV-infected adults

The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato.

9 Apr 2019

Antiviral treatment improves survival for kidney transplant recipients infected with HBV or HCV

Prior to the development of antiviral therapy, kidney transplant recipients infected with either hepatitis B or hepatitis C experienced poor outcomes.

15 Mar 2019

New clinical trial aims to examine safety and use of two HIV prevention tools

A clinical trial has begun to examine the safety and use of two HIV prevention tools--oral pre-exposure prophylaxis and a vaginal ring--in adolescent girls and young women in southern Africa.

8 Feb 2019

MTN launches new study to empower teen girls with choices in HIV prevention

AIDS is already the leading cause of death among girls and young women in much of Africa, and matters could only get worse, given that for every day that passes, 1,000 more girls ages 15 to 24 are likely to become infected with HIV.

8 Feb 2019

PrEP shown to be safe and effective for widespread use

New research presented at the HIV Drug Therapy Conference in Glasgow today shows that pre-exposure prophylaxis could be given to millions of people worldwide with no increased risk of safety issues during treatment.

30 Oct 2018

New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma

Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples.

12 Apr 2018

Study reveals new strategy to prevent mother-to-child transmission of hepatitis B virus

A clinical study coordinated by the French National Research Institute for Sustainable Development and Chiang Mai University with their Thai, American, and French partners, strengthens the case for a new strategy to prevent mother-to-child transmission of the hepatitis B virus.

8 Mar 2018

NIH launches large study to compare treatments for pregnant women with HIV

The National Institutes of Health has launched a large international study to compare the safety and efficacy of three antiretroviral treatment regimens for pregnant women living with HIV and the safety of these regimens for their infants.

24 Jan 2018

New HIV prevention guidelines from Canada released

New guidelines for Canada have been published in the Canadian Medical Association Journal online this week that outline the use of new anti-HIV medications among high risk populations who are at risk of contracting HIV from getting the dreaded infection. These new guidelines aim to provide the clinicians with resources and support he added.

27 Nov 2017

Study: PrEP program for men who have sex with men could lead to long-term cost savings

Providing pre-exposure prophylaxis (PrEP) medication to men who have sex with men who are at high risk of HIV infection (equivalent to less than 5% of men who have sex with men at any point in time) in England would be cost-effective, and could help to prevent up to one in four cases of HIV, according to a study published in The Lancet Infectious Diseases journal.

19 Oct 2017

HIV pre-exposure prophylaxis (PrEP) could be cost saving for NHS in long run

For men who have sex with men in the UK, a programme that involved providing pre-exposure prophylaxis (PrEP) treatment for HIV could be cost effective and cost saving finds a new study. The economic evaluation was made by a team led by Valentina Cambiano, of University College London and published in the latest issue of Lancet Infectious Diseases.

18 Oct 2017

HIV prevention drug to be trialed by Britain's NHS

After a High Court case, an HIV prevention drug is soon to be available on the NHS. NHS England has issued a statement saying that pre-exposure prophylaxis (PrEP) treatment for HIV shall be available to an initial 10,000 people for a trial period of three years.

3 Aug 2017

UTHealth participates in study to evaluate effectiveness of new injectable HIV medication

The HIV Prevention Trials Network, which includes McGovern Medical School at The University of Texas Health Science Center at Houston, has launched a study to evaluate whether a new injectable medication can work as well as an existing oral pill to safely protect against HIV among men who have sex with men (MSM) and transgender women (TGW) who have sex with men.

18 Apr 2017